Marquette University

e-Publications@Marquette

School of Dentistry Faculty Research and
Publications

Dentistry, School of

11-15-2020

Drug-delivery Ca-Mg Silicate Scaffolds Encapsulated in PLGA

A. Jadidi

K. N. Toosi University of Technology

E. Salahinejad

K.N.Toosi University of Technology

E. Sharifi

Hamadan University of Medical Sciences

Lobat Tayebi

Marquette University, lobat.tayebi@marquette.edu

Follow this and additional works at: https://epublications.marquette.edu/dentistry_fac

Part of the [Dentistry Commons](#)

Recommended Citation

Jadidi, A.; Salahinejad, E.; Sharifi, E.; and Tayebi, Lobat, "Drug-delivery Ca-Mg Silicate Scaffolds Encapsulated in PLGA" (2020). *School of Dentistry Faculty Research and Publications*. 443.
https://epublications.marquette.edu/dentistry_fac/443

Marquette University

e-Publications@Marquette

Dentistry Faculty Research and Publications/School of Dentistry

This paper is NOT THE PUBLISHED VERSION.

Access the published version via the link in the citation below.

International Journal of Pharmaceutics, Vol. 589 (November 15, 2020): 119855. [DOI](#). This article is © Elsevier and permission has been granted for this version to appear in [e-Publications@Marquette](#). Elsevier does not grant permission for this article to be further copied/distributed or hosted elsewhere without express permission from Elsevier.

Drug-delivery Ca-Mg Silicate Scaffolds Encapsulated in PLGA

A. Jadidi

Faculty of Materials Science and Engineering, K. N. Toosi University of Technology, Tehran, Iran

E. Salahinejad

Faculty of Materials Science and Engineering, K. N. Toosi University of Technology, Tehran, Iran

E. Sharifi

Department of Tissue Engineering and Biomaterials, School of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran

L. Tayebi

Department of Developmental Sciences, Marquette University School of Dentistry, Milwaukee, WI

Abstract

The aim of this work is to develop dual-functional scaffolds for bone tissue regeneration and local antibiotic delivery applications. In this respect, bioresorbable bredigite ($\text{Ca}_7\text{MgSi}_4\text{O}_{16}$) porous scaffolds were fabricated by a foam replica method, loaded with vancomycin hydrochloride and encapsulated in poly lactic-co-glycolic acid (PLGA) coatings. Field emission scanning electron microscopy, Archimedes porosimetry and Fourier-transform infrared spectroscopy were used to characterize the structure of the scaffolds. The drug delivery kinetics and cytocompatibility of the prepared scaffolds were also studied *in vitro*. The bare sample exhibited a burst release of vancomycin and low biocompatibility with

respect to dental pulp stem cells based on the MTT assay due to the fast bioresorption of bredigite. While keeping the desirable characteristics of pores for tissue engineering, the biodegradable PLGA coatings modified the drug release kinetics, buffered physiological pH and hence improved the cell viability of the vancomycin-loaded scaffolds considerably.

Graphical abstract

Keywords

Hard tissue reconstruction, Controlled drug delivery, Glycopeptide antibiotic, Biosilicate, Aliphatic polyester, Metabolic alkalosis

1. Introduction

One of the major complications of bone tissue engineering after implantation is bacterial bone infection or osteomyelitis, which can cause severe pain in patients and demand a high cost of treatment (Hetrick and Schoenfisch, 2006, Lucke et al., 2003, Shirtliff and Mader, 2000). To overcome this problem, systematic drug delivery is a prevalent method with several disadvantages like the possibility of high systemic toxicity and longer hospitalization. In contrast, local drug delivery is a suitable alternative that lacks the aforementioned drawbacks. These devices provide a sustained concentration of drugs needed for the inhibition of pathogens at the intended site in a prolonged and controlled fashion with no or minimal drug concentration in the systemic circulation (Jain, 2008, Marwah et al., 2016, Sankar et al., 2011). Fortunately, tissue-engineering scaffolds have the ability to act as the matrix of local drug delivery systems for bone infection treatment at the implantation site. In this regard, chitosan-coated bioactive glass scaffolds loaded with gatifloxacin and fluconazole (Soundrapandian et al., 2010), gelatin-hydroxyapatite scaffolds impregnated with ciprofloxacin (Krishnan et al., 2015) and calcium sulfate scaffolds loaded with tobramycin (Ferguson et al., 2014) are noticeable.

In this study, bredigite ($\text{Ca}_7\text{MgSi}_4\text{O}_{16}$) was chosen to fabricate the foundation of a dual-functional system with the aim of bone tissue regeneration and local drug delivery. From the viewpoint of mechanical properties, it is well-established that Mg-Ca silicates including bredigite are superior to apatites and bioglasses which are commonly used for implantation (Schumacher et al., 2014, Wu et al., 2007). As well as the direct role of Ca in bone-related processes, the presence of Mg and Si in this group of bioceramics is beneficial for some cellular processes and human metabolism, including bone

healing processes (Diba et al., 2014, Diba et al., 2012). In the orthorhombic structure of bredigite, the most abundant cation is Ca^{2+} , which provides high resorbability due to the lower activation energy of Ca-O bond for hydrolysis than Mg-O bond (Wu and Chang, 2007a). Among the variety of antibiotics, vancomycin was also selected to treat osteomyelitis because this is a very active glycopeptide antibiotic against *staphylococcus aureus*. In addition, this has the least deleterious effect on the function of osteoblasts and skeletal cells compared to other antibiotics used in the treatment of osteomyelitis like ciprofloxacin and tobramycin (Antoci et al., 2007, Edin et al., 1996).

The adsorption of drugs on drug delivery devices with weak physical bonds like the van der Waals type, rather than a chemical interaction, gives rise to a burst release of the drug during implantation. This is disadvantageously accompanied by the release of the entire drug before controlling the infection and a detrimental effect on biocompatibility due to the high concentration of the drug around the surrounding tissue (Huang and Brazel, 2001). It is noticeable that in the treatment of osteomyelitis caused by *staphylococcus aureus*, vancomycin should be released continually through 4–6 weeks at concentrations exceeding the minimum inhibitory concentration (MIC, 0.75–2 $\mu\text{g}/\text{ml}$) and minimum bactericidal concentration (MBC, 8 $\mu\text{g}/\text{ml}$) (Coudron et al., 1987, Gold and Moellering, 1996, Mason et al., 2009). MIC is the minimal concentration of a drug which prevents the visible growth of a bacterium and MBC is the lowest antibacterial density necessary to kill the bacterium. On the other hand, the high bioresorption rate of bredigite leads to metabolic alkalosis due to the high concentration of alkaline ionic (Ca^{2+} and Mg^{2+}) around the surrounding tissue followed by the reduction of hydrogen ions (H^+) outside the normal range (Galla, 2000). The use of polymer coatings is a promising approach to control both the resorption rate of scaffolds and the drug release rate of these devices.

To the best of our knowledge, there are no reports in the literature on the use of bredigite scaffolds as the matrix of drugs, which is the subject of this work. In this regard, to control the burst release of vancomycin and high physiological pH caused by the fast bioresorption of bredigite, bredigite scaffolds were coated with poly lactic-co-glycolic acid (PLGA). PLGA is a biodegradable synthetic aliphatic polyester made from the monomers of polylactide (PLA) and polyglycolide (PGA) with successful consequences as coating for drug delivery and tissue-engineering applications (Bose et al., 2018, Jadidi and Salahinejad, 2020, Khojasteh et al., 2016, Maurmann et al., 2017, Olalde et al., 2013, Su et al., 2019, Zamboni et al., 2017). Alternatively, polycaprolactone (PCL) is another polymer which has been extensively used for biomedical applications due to suitable biodegradability and nontoxicity (Park et al., 2012). However, PCL with a considerable biostability is postulated to disadvantageously suppress the appropriate bioresorbability of bredigite. The use of PLGA is also hypothesized to buffer the metabolic alkalosis phenomenon caused by the fast bioresorption of bredigite (Jadidi and Salahinejad, 2020, Keihan et al., 2020) since the degradation of this biopolymer acidifies the physiological medium (Zhao et al., 2011, Zhao et al., 2012).

2. Experimental procedures

2.1. Materials

Tetraethyl orthosilicate ($(\text{C}_2\text{H}_5\text{O})_4\text{Si}$, TEOS, Merck, Germany, Purity > 98%), magnesium nitrate hexahydrate ($\text{Mg}(\text{NO}_3)_2 \cdot 6\text{H}_2\text{O}$, Merck, Germany, Purity > 98%), calcium nitrate tetrahydrate ($\text{Ca}(\text{NO}_3)_2 \cdot 4\text{H}_2\text{O}$, Merck, Germany, Purity > 98%), and nitric acid (HNO_3 , 2 M, Merck, Germany) were

used for the sol–gel synthesis of bredigite. The drug and coating materials were vancomycin hydrochloride ($C_{66}H_{75}Cl_2N_9O_{24}$, Sigma Aldrich) and PLGA (5004A, lactide/glycolide ratio of 50:50, molecular weight = 44 kDa, acid-terminated, acid number: min 3 mg KOH/g, Corbion, Netherlands), respectively.

2.2. Synthesis of powder used for scaffolding

A sol–gel technique similar to Refs. (Jadidi and Salahinejad, 2020, Wu and Chang, 2007b, Wu et al., 2007) was used for the synthesis of bredigite. For the preparation of 1.000 g bredigite powder, 1.000 ml TEOS, 0.651 ml distilled water and 0.361 ml nitric acid were stirred at room temperature for 30 min. Thereafter, 0.289 g magnesium nitrate hexahydrate and 1.864 g calcium nitrate tetrahydrate were added to the solution and again stirred for 5 h. The solution was then maintained at 60 °C for 1 day, dried at 120 °C for 2 days and calcined at 700 °C for 3 h.

2.3. Fabrication of bredigite scaffolds

In order to fabricate bredigite scaffolds, the sacrificial foam replication method was employed. For this purpose, the calcined powder was suspended in a sodium alginate aqueous solution (3% w/w) with the bredigite/sodium alginate solution mass ratio of 1:3 under sonication for 3 min. Polyurethane foam templates (density: 25 ppi, porosity > 97%) were cut in a dimension $\sim 10 \times 10 \times 10 \text{ mm}^3$, immersed in a glass beaker containing the bredigite slurry and then forced by a compressed air flow to eliminate the extra slurry. After drying at 60 °C for 12 h, the impregnated foams were heated at 300 °C for 1 h for the removal of the urethane struts and then at 1350 °C for 3 h for sintering at the heating rate of 3 °C/min. X-ray diffraction analyses have previously confirmed the successful synthesis of bredigite via this processing route (Jadidi and Salahinejad, 2020, Wu and Chang, 2007b, Wu et al., 2007).

2.4. Drug loading in scaffolds

For the drug loading into the scaffolds, vancomycin hydrochloride was dissolved in distilled water with the concentration of 0.31 mg/ml. The scaffolds were maintained in the vancomycin solution with the ratio of 5 mg/ml for 24 h and then dried in air for 24 h.

2.5. PLGA coating of scaffolds

For the PLGA coating of the vancomycin-loaded scaffolds, 5 and 10% w/v solutions of PLGA and acetone were prepared at room temperature. Thereafter, the scaffolds were dipped into 10 ml of the PLGA solution for 3 sec and dried at 60 °C for 2 h for the solvent removal.

2.6. Structural characterization

The morphology of the samples was analyzed by field emission scanning electron microscopy (FESEM, MIRA3 TESCAN, Czech Republic, accelerating voltage = 15 kV) after gold sputtering. Porosimetry was also performed using the water Archimedes method, according to the following formula (Mirhadi et al., 2012):(1)

where P is the pore percentage, W_1 and W_2 are the weight of the scaffolds before and after immersion in water, respectively, and W_3 is the weight of the suspended scaffolds.

Fourier-transform infrared spectroscopy (FTIR, Thermo Nicolet, Avatar, USA) was also conducted on the milled scaffolds in the spectral range of 3600–400 cm^{-1} with the resolution of 4 cm^{-1} in a moisture-free environment at 25 °C.

2.7. Drug release analysis

In order to determine the *in vitro* release profile of vancomycin, the bare and PLGA-coated bredigite scaffolds impregnated with vancomycin were immersed into a glass bottle containing 20 ml phosphate buffered saline (PBS) with the ratio of 4 mg/ml at pH of 7.4 and 37 °C. At each predetermined time point, 3 ml of the solution was taken out and replaced with 3 ml of the fresh PBS solution. The amount of vancomycin in the solution was investigated by a UV spectrophotometer (UV–1100, MAPADA INSTRUMENT, Shanghai, China) at the wavelength of 280 nm with three repetitions. To calculate the accumulative release percentage of the drug, the total amount of vancomycin loaded into the scaffolds was also measured after the scaffolds were completely degraded in the medium. In order to establish the calibration curve of measurements, five concentrations of vancomycin in the range of 1–20 $\mu\text{g/ml}$ were chosen. According to the Beer-Lambert law (Thomas, 1996), the following calibration equation was found with the correlation coefficient of $R^2 = 0.998$ and used:(2)

2.8. Physiological pH evaluation

The variations of physiological pH due to exposure to the scaffolds were investigated by immersing them in the simulated body fluid (SBF) at 37 °C for 7 days using an electrolyte type pH meter (PHS-2C, Jingke Leici Co., Shanghai, China) with three repetitions. To do so, the scaffold/SBF ratio of 1:200 g/ml (Wu et al., 2006, Wu et al., 2011, Wu et al., 2010) was used.

2.9. Biocompatibility assessments

The MTT assay was conducted to assess the cytocompatibility of the prepared scaffolds of $3 \times 3 \times 3 \text{ mm}^3$ in size. The scaffolds were sterilized via exposure to UV radiation for 2 h. 3500 human dental pulp stem cells obtained from National Cell Bank of Iran were seeded on each set of the scaffolds with three repetitions in a 96-well culture plate with the scaffold-free cells-containing medium as the control and were then incubated at 37 °C under 5% CO_2 with Dulbecco's modified Eagle media (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) for 1, 3 and 7 days. The cytotoxicity assessment was done by using 3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium bromide (MTT, Sigma, USA) colorimetric assay based on the instructions of Ref. (Shahrouzifar et al., 2019). For this purpose, the culture medium was first removed, and then 100 μL of the MTT solution (5 mg/ml) was added to each well and incubated for 2 h at 37 °C under 5% CO_2 . Then, the medium was removed, and formazan precipitates were dissolved in dimethyl sulfoxide (Sigma, USA). The optical density of viable cells was measured by a microplate reader (ChroMate-4300, FL, USA) at the wavelength of 545 nm. One-way analysis of variance with a statistical significance level less than 5% (p-value < 0.05) was used to compare the cytocompatibility data.

The cell morphology on the optimal scaffold was also evaluated according to the protocol of Ref. (Shahrouzifar and Salahinejad, 2019). Briefly, 20,000 cells were seeded onto the sterilized scaffold and incubated in DMEM, 10% FBS, 100 IU/mL penicillin, and 100 IU/mL streptomycin. After 24 h of cell seeding, cells were fixed on the scaffold by 300 μL glutaraldehyde (2.5% in PBS) for 3 h at room temperature, then washed with PBS for 5 min and dehydrated in ascending ethanol series (30, 50, 70,

80, 90, and 100%). Finally, the sample was coated with a thin layer of gold and studied by electron microscopy.

3. Results and discussion

3.1. Structural analyses

The FESEM micrograph of the powder calcined at 700 °C used as the feedstock of scaffolding is shown in Fig. 1a, revealing highly agglomerated nanoparticles of almost 25 nm in size. Fig. 1b, c and d present the macrograph and micrograph of the scaffolds sintered at 1350 °C, consisting of irregular shaped particles of about 1–10 µm in size. The mean size of pores inside the struts is 3 µm, while the struts form pores of almost 200–1000 µm in size which are essential for bone tissue engineering. It would be worth mentioning that natural cancellous and cortical bones have 75–85% and 5–10% porosity levels with 300–600 and 10–50 µm sizes, respectively (Lee et al., 2012, Weiner and Wagner, 1998).

Fig. 1. FESEM micrograph of the sol-gel derived powder calcined at 700 °C (a), macrograph of the scaffold sintered at 1350 °C (b) and FESEM micrographs of the sintered scaffold in two magnifications (c, d).

Fig. 2 reveals the FESEM micrograph of the bare and PLGA-coated bredigite scaffolds. As well as the preservation of pores interconnectivity (Fig. 2a, c and e), the filling of fine pores of the struts as the drug loading matrix is evident after PLGA coating (Fig. 2d and f). Based on the Archimedes porosimetry method, the mean porosity levels of about 90, 82 and 77% were also measured for the bare, bredigite-5% PLGA and bredigite-10% PLGA scaffolds, respectively, where all are in the desired range of tissue-engineering scaffolds. On the contrary, 15% PLGA coating has been reported to disadvantageously block the pores of the scaffold (Jadidi and Salahinejad, 2020); thus, this sample is not considered in this

study. In addition, the thickness of the PLGA coatings deposited by the polymer concentrations of 5 and 10% is measured to be almost 7 and 16 μm , respectively (Fig. 3). It is also noticeable that the mean compressive mechanical strength of the bare, 5% PLGA-coated and 10% PLGA-coated bredigite scaffolds, albeit without any drug impregnation, is almost 0.3, 1.2 and 1.7 MPa, respectively (Jadidi and Salahinejad, 2020), where the strength of the PLGA-coated scaffolds is acceptable for bone tissue-engineering applications.

Fig. 2. FESEM micrographs of the bare (a, b), 5% PLGA-coated (c, d) and 10% PLGA-coated (e, f) bredigite scaffolds in two magnifications.

Fig. 3. Cross-sectional FESEM micrographs of the 5% (a, b) and 10% (c, d) PLGA-coated bredigite struts, where A, B and C represent the PLGA coating surface, bredigite strut cross section and PLGA coating cross section, respectively.

In order to confirm the formation of bredigite, the incorporation of vancomycin and the deposition of PLGA, the FTIR spectroscopy on the samples was used (Fig. 4). For the ceramic scaffold before impregnating with the drug and PLGA (Fig. 4a), the characteristic peaks of 1100–1000, 960 and 873 cm^{-1} are assigned to the SiO_4 tetrahedron stretching. The peak of 616 cm^{-1} is related to the SiO_4 tetrahedron bending. Also, 516 and 553 cm^{-1} are attributed to the O–Mg–O bending and Ca–O stretching vibrations, respectively. These assignments are in good agreement with the functional groups of bredigite (Khandan and Ozada, 2017, Mirhadi et al., 2012, Rahmati et al., 2018). For the vancomycin-loaded scaffolds (Fig. 4b and c), the broad peak of 3406 cm^{-1} is attributed to the stretching vibration of the hydroxyl group. Also, peaks at 1655, 1504 and 1231 cm^{-1} are assigned to the vibrational modes of C=O, aromatic C=C and phenolic cycle, respectively (Cerchiara et al., 2015, Ordikhani and Simchi, 2014, Yao et al., 2013), proving the successful incorporation of vancomycin into the scaffolds. The lack of any shifts in the absorption bands of vancomycin suggests that no chemical interactions occur between the drug and other substances, as an evidence for the physical adsorption of the drug. Also, for the PLGA-coated sample (Fig. 4c), the characteristic peaks of PLGA are identified at 1182 and 1089 cm^{-1} (C–O–C stretching), 1752 cm^{-1} (C=O stretching) and 1454 cm^{-1} (C–H stretching), which are compatible with the FTIR assignments of Refs. (Akl et al., 2016, Meng et al., 2010, Singh et al., 2014, Wang et al., 2019) for this aliphatic polyester.

Fig. 4. FTIR spectra of the bare vancomycin-free (a), bare vancomycin-loaded (b) and PLGA-coated vancomycin-loaded (c) bredigite scaffolds.

3.2. Drug delivery assessments

The accumulative amount and percentage profiles of vancomycin released from the scaffolds are illustrated in Fig. 5. The percentages were calculated with respect to the total loaded content of vancomycin which was $66.6 \pm 2.1\%$ of the drug dissolved in the solution. For the bare scaffold, a burst release of vancomycin is detected within 9 h, so that about $94.7 \pm 2.5\%$ of the loaded vancomycin level is released. Nevertheless, after coating of the scaffolds with PLGA, the burst release is beneficially declined to the first 6 h with only 21.0 ± 2.9 and $18.5 \pm 1.8\%$ of the loaded drug amount for the bredigite-5% PLGA and bredigite-10% PLGA scaffolds, respectively. These modified levels of the burst release in the first 6 h of implantation, called “decisive period”, are essential to prevent the adhesion of bacteria and thereby inhibit infections (Linke and Goldman, 2011, Poelstra et al., 2002).

Fig. 5. Concentration (a) and percentage (b) of vancomycin released from the different scaffolds.

In accordance with Fig. 5, after the initial burst release of the drug from the scaffolds, the release rate of vancomycin decreases and a sustained release is followed for the coated scaffolds. Typically, after one day of exposure, vancomycin is almost completely released from the bare scaffold, which is insufficient for the antibiotic therapy of osteomyelitis (Ford and Cassat, 2017, Long et al., 2016, Pande et al., 2015). In a similar study, Yao et al. (2013) investigated the vancomycin release behavior of bare and coated bioglass scaffolds and showed that vancomycin was released completely from the bare scaffold in less than 24 h. In contrast, only 33.3 ± 4.6 and $29.6 \pm 2.6\%$ of the initial loaded drug amount are desirably released from the 5 and 10% PLGA-coated bredigite scaffolds, respectively. Typically, after 7 days of immersion, nearly 6.16 ± 2.2 and $52.77 \pm 2.7\%$ of the drug still remain in the bredigite-5% PLGA and bredigite-10% PLGA scaffolds, respectively. The different kinetics of vancomycin release from the PLGA-coated samples is attributed to the different encapsulation modes of the struts with the PLGA deposits (Fig. 2d and f) and the different thicknesses of the coatings (Fig. 3). It is also worth mentioning that the drug release contents from the PLGA-coated scaffolds over the whole study period are above the MIC and MBC levels of vancomycin against *staphylococcus aureus* ($0.75\text{--}2$ and $8\text{ }\mu\text{g/ml}$, respectively (Coudron et al., 1987, Mason et al., 2009)), which is desirable for treating osteomyelitis.

3.3. Investigation of physiological pH variations

Fig. 6 depicts the pH value of the SBF during exposure to the scaffolds as a biodegradation/bioresorption-related evaluation. A sharp increase of pH from 7.47 ± 0.02 to 9.17 ± 0.08 is observed for the bare bredigite scaffold during 7 days of soaking. Due to the domination of Ca in the bredigite structure ($\text{Ca}_7\text{MgSi}_4\text{O}_{16}$) and the high affinity of the Ca-O bond for hydrolysis, the bioresorption rate of bredigite is very high (Keihan and Salahinejad, 2020, Wu and Chang, 2007a, Zirak et al., 2020). This results in a high local concentration of Ca^{+2} and Mg^{+2} ions in the surrounding biological environment. Accordingly, the activation of the ion exchange mechanism reduces the hydrogen ion concentration of the environment and thereby enhances pH. Regarding the bare scaffold impregnated with the drug, the presence of vancomycin despite an acidic character (Marshall, 1965) could not significantly decline physiological pH, due to the low concentration of the drug released into the medium. In contrast, the PLGA coating of the vancomycin-loaded scaffolds effectively considerably buffers pH. According to Fig. 6, the buffering effect is enhanced by increasing the PLGA concentration from 5% to 10% due to the following reasons:

- i. the release rate of the cations from the bredigite scaffolds is somewhat restricted with the increase of the coating thickness, where the PLGA coatings act as a physical barrier.
- ii. the amount of the acidic coproducts of PLGA (i.e. glycolic and lactic acids) released due to hydrolytic biodegradation is enhanced by increasing the content of PLGA.

Fig. 6. pH variations of the SBF in contact with the different scaffolds.

3.4. Biocompatibility evaluations

The MTT assay results of the cells cultured on the different scaffolds are indicated in Fig. 7, with the significance level of less than 5% (p -value < 0.05). Over the entire periods of culture, the cytocompatibility of the samples with respect to dental pulp stem cells ranks as follows: vancomycin-loaded 10% PLGA-coated bredigite > vancomycin-loaded 5% PLGA-coated > bredigite > vancomycin-loaded bredigite. Essentially, the fast bioresorption of bredigite leads to high physiological pH (Fig. 6) and the high concentration of Ca^{2+} released into the medium (Peshwa et al., 1993, Zhivotovsky and Orrenius, 2011), which are responsible for the relatively low cell viability on the bredigite scaffold, in agreement with Ref. (Wu and Chang, 2007a). The impregnation of the bredigite scaffold with the antibiotic drug under the bare conditions further decreases the cell cytocompatibility, due to the burst release of vancomycin in the medium (Fig. 5). Consistently, the detrimental influence of high vancomycin dosages on biocompatibility has been previously pointed out (Bakhsheshi-Rad et al., 2017). The controlling effects of the PLGA coatings on the burst release of the drug (Fig. 5), bredigite bioresorption and physiological pH (Fig. 6) cause the higher cytocompatibility of the coated scaffolds. This is supported by the fact that the cell viability is further improved by increasing the PLGA concentration from 5% to 10%.

Fig. 7. MTT results of the cell cultures on the different scaffolds, where *, Δ, ⊗ and ♠ demonstrate significant differences with respect to the control, bare vancomycin-free bredigite, vancomycin-loaded bredigite and vancomycin-loaded 5% PLGA-coated bredigite scaffolds, respectively.

Form this work, it is finally concluded that the 10% PLGA coating is the optimal surface modification for the vancomycin-loaded bredigite scaffolds for bone tissue-engineering and local drug delivery applications. This assignment is due to the fact that this sample benefits from the appropriate pores configuration, drug release kinetics, cytocompatibility and cell attachment characterized by a spread morphology of cells with high cytoplasmic extensions (Fig. 8).

Fig. 8. FESEM micrograph of a cell cultured on the vancomycin-impregnated 10% PLGA-coated bredigite scaffold, in which the arrows indicate cells.

4. Conclusions

In this work, bredigite ($\text{Ca}_7\text{MgSi}_4\text{O}_{16}$) porous scaffolds were fabricated by the sponge replica method, impregnated with vancomycin hydrochloride and coated with PLGA for bone tissue engineering. The bare drug-loaded scaffold exhibited a one-step burst release of vancomycin, so that the relatively entire amount of the drug loaded was released in less than 24 h. The burst release of the drug and the fast bioresorption of bredigite were recognized to be responsible for the relatively low cytocompatibility of this sample with respect to dental pulp stem cells. The PLGA coating, nevertheless, altered the drug delivery kinetics characterized by the limitation of the burst drug release stage and by the development of a sustained drug release behavior. This surface modification process also improved the cell viability, which was attributed to the modification of the drug release and the buffering effect of PLGA on physiological pH. The most improvement in the biological behaviors was obtained by employing the PLGA coating deposited from the 10% PLGA-acetone solution, with the suitable characteristics of pores for bone tissue engineering and the appropriate antibiotic release kinetics for osteomyelitis treatment.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- Akl et al., 2016. M.A. Akl, A. Kartal-Hodzic, T. Oksanen, H.R. Ismael, M.M. Afouna, M. Yliperttula, A.M. Samy, T. Viitala. **Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery.** J. Drug Delivery Sci. Technol., 32 (2016), pp. 10-20
- Antoci et al., 2007. V. Antoci Jr, C.S. Adams, N.J. Hickok, I.M. Shapiro, J. Parvizi. **Antibiotics for local delivery systems cause skeletal cell toxicity in vitro.** Clin. Orthop. Relat. Res., 462 (2007), pp. 200-206
- Bakhsheshi-Rad et al., 2017. H. Bakhsheshi-Rad, E. Hamzah, A. Ismail, M. Aziz, Z. Hadisi, M. Kashefian, A. Najafinezhad. **Novel nanostructured baghdadite-vancomycin scaffolds: In-vitro drug release, antibacterial activity and biocompatibility.** Mater. Lett., 209 (2017), pp. 369-372
- Bose et al., 2018. S. Bose, N. Sarkar, D. Banerjee. **Effects of PCL, PEG and PLGA polymers on curcumin release from calcium phosphate matrix for in vitro and in vivo bone regeneration.** Mater. Today Chem., 8 (2018), pp. 110-120
- Cerchiara et al., 2015. T. Cerchiara, A. Abruzzo, M. Di Cagno, F. Bigucci, A. Bauer-Brandl, C. Parolin, B. Vitali, M. Gallucci, B. Luppi. **Chitosan based micro-and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods.** Eur. J. Pharm. Biopharm., 92 (2015), pp. 112-119
- Coudron et al., 1987. P.E. Coudron, J.L. Johnston, G.L. Archer. **In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.** J. Antimicrob. Chemother., 20 (1987), pp. 505-511
- Diba et al., 2014. M. Diba, O.-M. Goudouri, F. Tapia, A.R. Boccaccini. **Magnesium-containing bioactive polycrystalline silicate-based ceramics and glass-ceramics for biomedical applications.** Curr. Opin. Solid State Mater. Sci., 18 (2014), pp. 147-167
- Diba et al., 2012. M. Diba, F. Tapia, A.R. Boccaccini, L.A. Strobel. **Magnesium-containing bioactive glasses for biomedical applications.** Int. J. Appl. Glass Sci., 3 (2012), pp. 221-253
- Edin et al., 1996. M.L. Edin, T. Miclau, G.E. Lester, R.W. Lindsey, L.E. Dahners. **Effect of cefazolin and vancomycin on osteoblasts in vitro.** Clin. Orthop. Relat. Res., 333 (1996), pp. 245-251
- Ferguson et al., 2014. J. Ferguson, M. Dudareva, N. Riley, D. Stubbs, B. Atkins, M. McNally. **The use of a biodegradable antibiotic-loaded calcium sulphate carrier containing tobramycin for the treatment of chronic osteomyelitis: a series of 195 cases.** Bone Joint J., 96 (2014), pp. 829-836
- Ford and Cassat, 2017. C.A. Ford, J.E. Cassat. **Advances in the local and targeted delivery of anti-infective agents for management of osteomyelitis.** Expert Rev. Anti-Infective Ther., 15 (2017), pp. 851-860
- Galla, 2000. J.H. Galla. **Metabolic alkalosis.** J. Am. Soc. Nephrol., 11 (2000), pp. 369-375
- Gold and Moellering, 1996. H.S. Gold, R.C. Moellering Jr. **Antimicrobial-drug resistance.** N. Engl. J. Med., 335 (1996), pp. 1445-1453
- Hetrick and Schoenfisch, 2006. E.M. Hetrick, M.H. Schoenfisch. **Reducing implant-related infections: active release strategies.** Chem. Soc. Rev., 35 (2006), pp. 780-789
- Huang and Brazel, 2001. X. Huang, C.S. Brazel. **On the importance and mechanisms of burst release in matrix-controlled drug delivery systems.** J. Control. Release, 73 (2001), pp. 121-136
- Jadidi and Salahinejad, 2020. A. Jadidi, E. Salahinejad. **Mechanical strength and biocompatibility of bredigite (Ca₇MgSi₄O₁₆) tissue-engineering scaffolds modified by aliphatic polyester coatings.** Ceram. Int., 46 (2020), pp. 16439-16446
- Jain, 2008. Jain, K.K., 2008. Drug delivery systems-an overview, Drug delivery systems. Springer, pp. 1–50.

- Keihan et al., 2020. R. Keihan, A. Ghorbani, E. Salahinejad, E. Sharifi, L. Tayebi. **Biomineralization, strength and cytocompatibility improvement of bredigite scaffolds through doping/coating.** Ceram. Int., 46 (2020), pp. 21056-21063
- Keihan and Salahinejad, 2020. R. Keihan, E. Salahinejad. **Inorganic-salt coprecipitation synthesis, fluoride-doping, bioactivity and physiological pH buffering evaluations of bredigite.** Ceram. Int., 46 (2020), pp. 13292-13296
- Khandan and Ozada, 2017. A. Khandan, N. Ozada. **Bredigite-Magnetite (Ca₇MgSi₄O₁₆-Fe₃O₄) nanoparticles: a study on their magnetic properties.** J. Alloy. Compd., 726 (2017), pp. 729-736
- Khojasteh et al., 2016 A. Khojasteh, F. Fahimipour, M.B. Eslaminejad, M. Jafarian, S. Jahangir, F. Bastami, M. Tahriri, A. Karkhaneh, L. Tayebi. **Development of PLGA-coated β -TCP scaffolds containing VEGF for bone tissue engineering.** Mater. Sci. Eng., C, 69 (2016), pp. 780-788
- Krishnan et al., 2015. A.G. Krishnan, L. Jayaram, R. Biswas, M. Nair. **Evaluation of antibacterial activity and cytocompatibility of ciprofloxacin loaded Gelatin-Hydroxyapatite scaffolds as a local drug delivery system for osteomyelitis treatment.** Tissue Eng. Part A, 21 (2015), pp. 1422-1431
- Lee et al., 2012. Lee, S., Porter, M., Wasko, S., Lau, G., Chen, P.-Y., Novitskaya, E.E., Tomsia, A.P., Almutairi, A., Meyers, M.A., McKittrick, J., 2012. Potential bone replacement materials prepared by two methods. MRS Online Proceedings Library Archive 1418.
- Linke and Goldman, 2011. D. Linke, A. Goldman. **Bacterial Adhesion: Chemistry, Biology and Physics.** Springer Science & Business Media (2011)
- Long et al., 2016. Y. Long, Z. Zhu, Y. Yu, S. Zhang. **Progress of different drug delivery route of vancomycin for the treatment of chronic osteomyelitis.** Zhonghua wai ke za zhi [Chinese J. Surg.], 54 (2016), pp. 716-720
- Lucke et al., 2003. M. Lucke, G. Schmidmaier, S. Sadoni, B. Wildemann, R. Schiller, A. Stemberger, N. Haas, M. Raschke. **A new model of implant-related osteomyelitis in rats.** J. Biomed. Mater. Res. B Appl. Biomater., 67 (2003), pp. 593-602
- Marshall, 1965. F.J. Marshall. **Structure studies on vancomycin.** J. Med. Chem., 8 (1965), pp. 18-22
- Marwah et al., 2016. H. Marwah, T. Garg, A.K. Goyal, G. Rath. **Permeation enhancer strategies in transdermal drug delivery.** Drug Delivery, 23 (2016), pp. 564-578
- Mason et al., 2009. E.O. Mason, L.B. Lamberth, W.A. Hammerman, K.G. Hulten, J. Versalovic, S.L. Kaplan. **Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.** J. Clin. Microbiol., 47 (2009), pp. 1628-1630
- Maurmann et al., 2017. N. Maurmann, D.P. Pereira, D. Burguez, S. De, F.D. Pereira, P.I. Neto, R.A. Rezende, D. Gamba, J.V. da Silva, P. Pranke. **Mesenchymal stem cells cultivated on scaffolds formed by 3D printed PCL matrices, coated with PLGA electrospun nanofibers for use in tissue engineering.** Biomed. Phys. Eng. Express, 3 (2017), Article 045005
- Meng et al., 2010. Z. Meng, Y. Wang, C. Ma, W. Zheng, L. Li, Y. Zheng. **Electrospinning of PLGA/gelatin randomly-oriented and aligned nanofibers as potential scaffold in tissue engineering.** Mater. Sci. Eng., C, 30 (2010), pp. 1204-1210
- Mirhadi et al., 2012. S. Mirhadi, F. Tavangarian, R. Emadi. **Synthesis, characterization and formation mechanism of single-phase nanostructure bredigite powder.** Mater. Sci. Eng., C, 32 (2012), pp. 133-139
- Olalde et al., 2013. B. Olalde, N. Garmendia, V. Sáez-Martínez, N. Argarate, P. Noeaid, F. Morin, A. Boccaccini. **Multifunctional bioactive glass scaffolds coated with layers of poly (d, l-lactide-co-glycolide) and poly (n-isopropylacrylamide-co-acrylic acid) microgels loaded with vancomycin.** Mater. Sci. Eng., C, 33 (2013), pp. 3760-3767

- Ordikhani and Simchi, 2014. F. Ordikhani, A. Simchi. **Long-term antibiotic delivery by chitosan-based composite coatings with bone regenerative potential.** Appl. Surf. Sci., 317 (2014), pp. 56-66
- Pande et al., 2015. K.C. Pande, J. Putera, B. Seri. **Optimal management of chronic osteomyelitis: current perspectives.** Orthopedic Res. Rev., 7 (2015), pp. 71-81
- Park et al., 2012. S.H. Park, D.S. Park, J.W. Shin, Y.G. Kang, H.K. Kim, T.R. Yoon, J.-W. Shin. **Scaffolds for bone tissue engineering fabricated from two different materials by the rapid prototyping technique: PCL versus PLGA.** J. Mater. Sci. - Mater. Med., 23 (2012), pp. 2671-2678
- Peshwa et al., 1993. M.V. Peshwa, Y.S. Kyung, D.B. McClure, W.S. Hu. **Cultivation of mammalian cells as aggregates in bioreactors: effect of calcium concentration of spatial distribution of viability.** Biotechnol. Bioeng., 41 (1993), pp. 179-187
- Poelstra et al., 2002. K.A. Poelstra, N.A. Barekzi, A.M. Rediske, A.G. Felts, J.B. Slunt, D.W. Grainger. **Prophylactic treatment of gram-positive and gram-negative abdominal implant infections using locally delivered polyclonal antibodies.** J. Biomed. Mater. Res., 60 (2002), pp. 206-215
- Rahmati et al., 2018. M. Rahmati, M. Fathi, M. Ahmadian. **Preparation and structural characterization of bioactive bredigite (Ca₇MgSi₄O₁₆) nanopowder.** J. Alloy. Compd., 732 (2018), pp. 9-15
- Sankar et al., 2011. V. Sankar, V. Hearnden, K. Hull, D.V. Juras, M. Greenberg, A. Kerr, P.B. Lockhart, L.L. Patton, S. Porter, M. Thornhill. **Local drug delivery for oral mucosal diseases: challenges and opportunities.** Oral Dis., 17 (2011), pp. 73-84
- Schumacher et al., 2014. T.C. Schumacher, E. Volkmann, R. Yilmaz, A. Wolf, L. Treccani, K. Rezwani. **Mechanical evaluation of calcium-zirconium-silicate (baghdadite) obtained by a direct solid-state synthesis route.** J. Mech. Behav. Biomed. Mater., 34 (2014), pp. 294-301
- Shahrouzifar and Salahinejad, 2019. M. Shahrouzifar, E. Salahinejad. **Strontium doping into diopside tissue engineering scaffolds.** Ceram. Int., 45 (2019), pp. 10176-10181
- Shahrouzifar et al., 2019. M. Shahrouzifar, E. Salahinejad, E. Sharifi. **Co-incorporation of strontium and fluorine into diopside scaffolds: bioactivity, biodegradation and cytocompatibility evaluations.** Mater. Sci. Eng., C, 103 (2019), Article 109752
- Shirliff and Mader, 2000. M. Shirliff, J. Mader. **Osteomyelitis, Persistent bacterial infections.** Am. Soc. Microbiol. (2000), pp. 375-396
- Singh et al., 2014. G. Singh, T. Kaur, R. Kaur, A. Kaur. **Recent biomedical applications and patents on biodegradable polymer-PLGA.** Int. J. Pharm. Pharm. Sci., 1 (2014), pp. 30-32
- Soundrapandian et al., 2010. C. Soundrapandian, S. Datta, B. Kundu, D. Basu, B. Sa. **Porous bioactive glass scaffolds for local drug delivery in osteomyelitis: development and in vitro characterization.** AAPS PharmSciTech, 11 (2010), pp. 1675-1683
- Su et al., 2019. W. Su, Y. Hu, M. Zeng, M. Li, S. Lin, Y. Zhou, J. Xie. **Design and evaluation of nano-hydroxyapatite/poly (vinyl alcohol) hydrogels coated with poly (lactic-co-glycolic acid)/nano-hydroxyapatite/poly (vinyl alcohol) scaffolds for cartilage repair.** J. Orthopaedic Surg. Res., 14 (2019), p. 446
- Thomas, 1996. M.J.K. Thomas. **Ultraviolet & Visible Spectroscopy.** John Wiley & Sons (1996)
- Wang et al., 2019. J. Wang, L. Helder, J. Shao, J.A. Jansen, M. Yang, F. Yang. **Encapsulation and release of doxycycline from electrospray-generated PLGA microspheres: effect of polymer end groups.** Int. J. Pharm., 564 (2019), pp. 1-9
- Weiner and Wagner, 1998. S. Weiner, H.D. Wagner. **The material bone: structure-mechanical function relations.** Annu. Rev. Mater. Sci., 28 (1998), pp. 271-298
- Wu and Chang, 2007a. C. Wu, J. Chang. **Degradation, bioactivity, and cytocompatibility of diopside, akermanite, and bredigite ceramics.** J. Biomed. Mater. Res. B Appl. Biomater., 83 (2007), pp. 153-160

- Wu and Chang, 2007b. C. Wu, J. Chang. **Synthesis and in vitro bioactivity of bredigite powders.** J. Biomater. Appl., 21 (2007), pp. 251-263
- Wu et al., 2007. C. Wu, J. Chang, W. Zhai, S. Ni. **A novel bioactive porous bredigite (Ca₇ MgSi₄ O₁₆) scaffold with biomimetic apatite layer for bone tissue engineering.** J. Mater. Sci. - Mater. Med., 18 (2007), pp. 857-864
- Wu et al., 2006. C. Wu, J. Chang, W. Zhai, S. Ni, J. Wang. **Porous akermanite scaffolds for bone tissue engineering: preparation, characterization, and in vitro studies.** J. Biomed. Mater. Res. Part B: Appl. Biomater.: Off. J. Soci. Biomater., Japanese Soc. Biomater., Australian Soc. Biomater. Korean Soc. Biomater., 78 (2006), pp. 47-55
- Wu et al., 2011. C. Wu, Y. Luo, G. Cuniberti, Y. Xiao, M. Gelinsky. **Three-dimensional printing of hierarchical and tough mesoporous bioactive glass scaffolds with a controllable pore architecture, excellent mechanical strength and mineralization ability.** Acta Biomater., 7 (2011), pp. 2644-2650
- Wu et al., 2010. C. Wu, Y. Ramaswamy, H. Zreiqat. **Porous diopside (CaMgSi₂O₆) scaffold: a promising bioactive material for bone tissue engineering.** Acta Biomater., 6 (2010), pp. 2237-2245
- Yao et al., 2013. Q. Yao, P. Nooeaid, J.A. Roether, Y. Dong, Q. Zhang, A.R. Boccaccini. **Bioglass®-based scaffolds incorporating polycaprolactone and chitosan coatings for controlled vancomycin delivery.** Ceram. Int., 39 (2013), pp. 7517-7522
- Zamboni et al., 2017. F. Zamboni, M. Keays, S. Hayes, A.B. Albadarin, G.M. Walker, P.A. Kiely, M.N. Collins. **Enhanced cell viability in hyaluronic acid coated poly (lactic-co-glycolic acid) porous scaffolds within microfluidic channels.** Int. J. Pharm., 532 (2017), pp. 595-602
- Zhao et al., 2011. L. Zhao, K. Lin, M. Zhang, C. Xiong, Y. Bao, X. Pang, J. Chang. **The influences of poly (lactic-co-glycolic acid)(PLGA) coating on the biodegradability, bioactivity, and biocompatibility of calcium silicate bioceramics.** J. Mater. Sci., 46 (2011), pp. 4986-4993
- Zhao et al., 2012. L. Zhao, C. Wu, K. Lin, J. Chang. **The effect of poly (lactic-co-glycolic acid)(PLGA) coating on the mechanical, biodegradable, bioactive properties and drug release of porous calcium silicate scaffolds.** Bio-Med. Mater. Eng., 22 (2012), pp. 289-300
- Zhivotovsky and Orrenius, 2011. B. Zhivotovsky, S. Orrenius. **Calcium and cell death mechanisms: a perspective from the cell death community.** Cell Calcium, 50 (2011), pp. 211-221
- Zirak et al., 2020. N. Zirak, A.B. Jahromi, E. Salahinejad. **Vancomycin release kinetics from Mg–Ca silicate porous microspheres developed for controlled drug delivery.** Ceram. Int., 46 (2020), pp. 508-512